About us

Alevin Therapeutics is creating breakthrough approaches to safe and effective medicines for patients with life-threatening diseases.
We aim for therapeutic applications in diseases with high unmet clinical need: fibrosis, in particular idiopathic pulmonary fibrosis (IPF), liver and kidney disease, and cancer.

Our team has created a platform of novel small molecules targeting specific pathways within complex integrin biology. We aim to develop our preclinical and discovery-stage assets towards clinical application, to offer new treatments and relief for millions of patients  affected by life-limiting conditions for which no effective therapy currently exists.

Company origins

Following decades of leadership in industrial and academic drug discovery, Alevin’s seasoned founding team leveraged the innovative research capabilities of the University of Nottingham (UoN) to create novel drug-like molecules targeting the integrin pathway. 

Over a 10-year period, Alevin’s founders pursued a new model of direct teaching and instruction and mission-led academic invention to develop a diverse portfolio of patented integrin inhibitors and enabling know-how.
Hauxton Mill
Mill SciTech Park
Alevin Therapeutics was launched to develop this pipeline of integrin medicine innovation towards clinical use. 

With two advanced preclinical assets and discovery capabilities to create additional programmes, Alevin is positioned to translate the fundamental research of UoN and our founders into new safe and effective therapies.

hello world!

What's in  a name?

With its name derived from the growth cycle of the Atlantic salmon (Salmo salar), a much-prized entity encountered near to our founders’ homes and roots, Alevin represents the potential for renewal, rejuvenation and creation across seasons and life.